Evaluation OF PNPLA3 level in Liver Cirrhosis and Hepatocellular Carcinoma in Egyptian Patients
Fady Galal El Malah;
Abstract
Hepatocellular carcinoma (HCC) is the most common form of primary malignancy of the liver, and the second leading cause of cancer- related mortality worldwide.
Patatin-like phospholipase domain-containing 3 (PNPLA3), also called adiponutrin, belongs to a novel class of patatin-like phospholipase family proteins, which have emerged as a new biomarker of human hepatic steatosis and nonalcoholic fatty liver disease. A large volume of research data has demonstrated that PNPLA3 is highly expressed in hepatic stellate and hepatoma cells, suggesting a potential role in cirrhosis and hepatocarcinogenesis.
The aim of this study was to study the role of PNPLA3 as a novel biomarker in liver cirrhosis and hepatocellular carcinoma in Egyptian patients.
This is a cross sectional study that was conducted on 40 Egyptian patients, 20 patients with liver cirrhosis and 20 patients with Hepatocellular Carcinoma. Patients were recruited in Internal Medicine Department, Gastroenterology unit, Ain Shams University Hospital. All patients had signed a written informed consent.
Patients were divided into 2 groups: Group (I) included 20 patients with HCV or HBV related liver cirrhosis (LC), and Group (II) included
20 patients with HCC. The selected patients were subjected to: Full medical history, Laboratory investigations including, abdominal ultrasonography, and assessment of PNPLA3 using ANTI human PNPLA3 ANTI-Body ELISA KIT for quantitative detection of PNPLA3 in Human serum.
Patatin-like phospholipase domain-containing 3 (PNPLA3), also called adiponutrin, belongs to a novel class of patatin-like phospholipase family proteins, which have emerged as a new biomarker of human hepatic steatosis and nonalcoholic fatty liver disease. A large volume of research data has demonstrated that PNPLA3 is highly expressed in hepatic stellate and hepatoma cells, suggesting a potential role in cirrhosis and hepatocarcinogenesis.
The aim of this study was to study the role of PNPLA3 as a novel biomarker in liver cirrhosis and hepatocellular carcinoma in Egyptian patients.
This is a cross sectional study that was conducted on 40 Egyptian patients, 20 patients with liver cirrhosis and 20 patients with Hepatocellular Carcinoma. Patients were recruited in Internal Medicine Department, Gastroenterology unit, Ain Shams University Hospital. All patients had signed a written informed consent.
Patients were divided into 2 groups: Group (I) included 20 patients with HCV or HBV related liver cirrhosis (LC), and Group (II) included
20 patients with HCC. The selected patients were subjected to: Full medical history, Laboratory investigations including, abdominal ultrasonography, and assessment of PNPLA3 using ANTI human PNPLA3 ANTI-Body ELISA KIT for quantitative detection of PNPLA3 in Human serum.
Other data
| Title | Evaluation OF PNPLA3 level in Liver Cirrhosis and Hepatocellular Carcinoma in Egyptian Patients | Other Titles | تقييم مستوى PNPLA3 فى مرضى تليف الكبد وسرطان الكبد المصريين | Authors | Fady Galal El Malah | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.